Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
Kusatsu/Shiga, Japan — May 19, 2016 – Takara Bio Inc. announces that HF10 US Phase II clinical trial data will be presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (May29 – June 2, 2016, Chicago, Illinois, U.S.)
【Outline of presentation】
|Name of conference||ASCO(American Society of Clinical Oncology) Annual Meeting 2016|
|Place||McCormick Place (Chicago, Illinois, U.S.)|
|Date||June 4 (local time)|
|Title||Preliminary results from Phase II Study of Combination Treatment with HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Melanoma|
|Summary||The interim results of Phase II clinical trial for oncolytic virus HF10 in the U.S.[Enrollment progress ]- 43 patients enrolled, and 37 were evaluable.
– Combination with HF-10 does not appear to exacerbate Ipilimumab toxicity.
– The combination treatment with Ipilimumab and oncolytic virus, HF-10 improved the response rate of Ipilimumab alone. It suggests that it is a potential novel therapeutic approach for metastatic melanoma.
The results will be also presented in the 2016 the Japanese Society of Medical Oncology Annual Meeting scheduled from July 28 at Kobe International Conference Center (Kobe) and in Japan Society of Gene and Cell Therapy scheduled from 28 July at Venue Toranomon Hills Forum (Tokyo).
This article is translated from press release in Japanese for your convenience.
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.